Could a common diabetes drug help manage cystic Fibrosis-Related diabetes?

NCT ID NCT06149793

Ongoing Disease control Sponsor: University of Minnesota Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This pilot study tests the safety and feasibility of empagliflozin (Jardiance) in 8 overweight or obese adults with cystic fibrosis-related diabetes (CFRD) who are already on insulin. Participants will receive either the drug or a placebo in a crossover design. The goal is to gather initial data to support a larger trial.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Empagliflozin (also known as Jardiance, a diabetes drug that helps lower blood sugar)
What this could lead to: If successful, this could point toward a new treatment option for managing diabetes in people with cystic fibrosis who are overweight or obese.
What could go wrong: This is a very small pilot study with only 8 participants, so results may not apply broadly. The drug may cause side effects or not work as hoped.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CYSTIC FIBROSIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

cystic fibrosis cystic fibrosis-related diabetes

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CYSTIC FIBROSIS CYSTIC FIBROSIS RELATED DIABETES

Contacts and locations

Locations

University of Minnesota

Minneapolis, Minnesota, 55455, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.